Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7KIE

Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with covalent compound 3

Summary for 7KIE
Entry DOI10.2210/pdb7kie/pdb
Related7KIA
DescriptorFibroblast growth factor receptor 2, N-{4-[(E)-2-{4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}ethenyl]phenyl}prop-2-enamide, CITRATE ANION, ... (5 entities in total)
Functional Keywordsfgfr kinase domain, fgfr, fgfr2, fgfr3, kinase inhibitor, covalent inhibitor, gatekeeper mutant, rtk, signaling protein, tumor growth, cholangiocarcinoma
Biological sourceHomo sapiens (Human)
Total number of polymer chains2
Total formula weight72106.76
Authors
Ke, J.,Wibowo, A.S.,Carter, J.J.,Larsen, N.A. (deposition date: 2020-10-23, release date: 2021-02-10, Last modification date: 2024-10-23)
Primary citationBrawn, R.A.,Cook, A.,Omoto, K.,Ke, J.,Karr, C.,Colombo, F.,Virrankoski, M.,Prajapati, S.,Reynolds, D.,Bolduc, D.M.,Nguyen, T.V.,Gee, P.,Borrelli, D.,Caleb, B.,Yao, S.,Irwin, S.,Larsen, N.A.,Selvaraj, A.,Zhao, X.,Ioannidis, S.
Discovery of Aminopyrazole Derivatives as Potent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR2 and 3.
Acs Med.Chem.Lett., 12:93-98, 2021
Cited by
PubMed Abstract: Fibroblast growth factor receptors (FGFR) 2 and 3 have been established as drivers of numerous types of cancer with multiple drugs approved or entering late stage clinical trials. A limitation of current inhibitors is vulnerability to gatekeeper resistance mutations. Using a combination of targeted high-throughput screening and structure-based drug design, we have developed a series of aminopyrazole based FGFR inhibitors that covalently target a cysteine residue on the P-loop of the kinase. The inhibitors show excellent activity against the wild-type and gatekeeper mutant versions of the enzymes. Further optimization using SAR analysis and structure-based drug design led to analogues with improved potency and drug metabolism and pharmacokinetics properties.
PubMed: 33488969
DOI: 10.1021/acsmedchemlett.0c00517
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.47 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon